Antibody–drug conjugates for cancer therapy

Thomas, Anish; Teicher, Beverly A; Hassan, Raffit

doi:10.1016/s1470-2045(16)30030-4

Cited by 606Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and ImmunotoxinsRadiopharmaceutical Chemistry and Applications

Antibody–drug conjugates for cancer therapy

Open access

Thomas, Anish, Teicher, Beverly A, Hassan, Raffit·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30030-4PMC PMC6601617

Open this paper in CoChat — free account

Abstract

Antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents. They use antibodies that are specific to tumour cell-surface proteins and, thus, have tumour specificity and potency not achievable with traditional drugs. Design of effective antibody-drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector molecules, and conjugation of the monoclonal antibody to cytotoxic agents. Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clinical use. Several promising antibody-drug conjugates are now in late-phase clinical testing. Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody-drug linker technology. Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30030-4

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

To date, 11 antibody-drug conjugates have been FDA-approved for 20 specific indications.
“To date, 11 ADCs have been Food and Drug Administration (FDA)-approved for 20 specific indications”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [61]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works
Ovarian Cancer
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149 · see citing works
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,528 · see citing works
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,365 · see citing works
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J. S., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,254 · see citing works
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 1,004 · see citing works
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2007) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 819 · see citing works
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 772 · see citing works
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 769 · see citing works
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S. A., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 763 · see citing works
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
Chang, K., & Pastan, I. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 747 · see citing works
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Krop, I. E., Kim, S., González-Martı́n, A., LoRusso, P. M., Ferrero, J.-., Smitt, M. C., Yu, R., Leung, A. C. F., & Wildiers, H. P. M. W. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724 · see citing works
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Petersdorf, S. H., Kopecky, K. J., Slovak, M. L., Willman, C. L., Nevill, T. J., Brandwein, J. M., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638 · see citing works
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Olsen, E. A., Duvic, M. A., Frankel, A. E., Kim, Y. H., Martin, A., Vonderheid, E. C., Jegasothy, B. V., Wood, G. S., Gordon, M., HEALD, P. W., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.376 · Cited by 610 · see citing works
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R. C., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600 · see citing works
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2015) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 556 · see citing works
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 550 · see citing works
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 539 · see citing works
Immunotoxin therapy of cancer
Pastan, I. H., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1891 · Cited by 529 · see citing works
Self-citation
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444 · see citing works
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429 · see citing works
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427 · see citing works
Self-citation
Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications
Shvartsur, A., & Bonavida, B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.40 · Cited by 412 · see citing works
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Kantarjian, H. M., Thomas, D. A., Jorgensen, J. L., Jabbour, E. J., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M. I., Faderl, S. H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70386-2 · Cited by 411 · see citing works
Brentuximab Vedotin (SGN-35)
Katz, J. B., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368 · see citing works
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K. M., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2003) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361 · see citing works
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Amiri‐Kordestani, L., Blumenthal, G. M., Xu, Q., Zhang, L., Tang, S. W., Ha, L., Weinberg, W. C., Chi, B., Candau-Chacon, R., Hughes, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0012 · Cited by 352 · see citing works
Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
Müller, P., Kreuzaler, M., Khan, T. A., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U. A., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 351 · see citing works
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Starodub, A., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340 · see citing works
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Advani, A. S., Coiffier, B., Czuczman, M. S., Dreyling, M. H., Foran, J. M., Giné, E., Gisselbrecht, C., Ketterer, N., Nasta, S. D., Rohatiner, A. Z. S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336 · see citing works
A general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A. J., Tran, H., Sun, Y., Phuong, T., Barnett, R. S., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 321 · see citing works
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 312 · see citing works
Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes
Letschert, K., Faulstich, H., Keller, D. B., et al. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj141 · Cited by 297 · see citing works
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Kreitman, R. J., Tallman, M. S., Robak, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1756 · Cited by 297 · see citing works
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y., Audette, C. A., Mayo, M., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S. D., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 265 · see citing works
Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy
Chari, R. V. J. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00095-1 · Cited by 235 · see citing works
Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S. D., Widdison, W. C., Chari, R. V. J., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0644 · Cited by 234 · see citing works
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Hassan, R., Miller, A. C., Sharon, E., Thomas, A., Reynolds, J. C., Ling, A. L., Kreitman, R. J., Miettinen, M., Steinberg, S. M., Fowler, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006941 · Cited by 234 · see citing works
Self-citation
Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Golfier, S., Kopitz, C., Kahnert, A., Heisler, I., Schatz, C., Stelte-Ludwig, B., Mayer-Bartschmid, A., Unterschemmann, K., Bruder, S., Linden, L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0926 · Cited by 232 · see citing works
Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
Kellogg, B. A., Garrett, L. M., Kovtun, Y., Lai, K. C., Leece, B. A., Miller, M. L., Payne, G. M., Steeves, R. M., Whiteman, K. R., Widdison, W. C., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100480a · Cited by 219 · see citing works
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C. A., Jones, G. E., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215 · see citing works
U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
de Claro, R. A., McGinn, K. M., Kwitkowski, V. E., Bullock, J. M., Khandelwal, A., Habtemariam, B. A., Ouyang, Y., Saber, H., Lee, K., Koti, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1803 · Cited by 210 · see citing works
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
Yardley, D. A., Weaver, R., Melisko, M., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D. L., Oliff, I. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 189 · see citing works
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
Hassan, R., Blumenschein, G. R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Thomas, A., Kim, S. K., Rajagopalan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02085 · Cited by 173 · see citing works
Self-citation
Understanding and Exploiting Natures Chemical Arsenal: The Past,Present and Future of Calicheamicin Research
Thorson, J. S., Sievers, E. L., Ahlert, J., et al. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003398564 · Cited by 166 · see citing works
Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
Geffers, I., Serth, K., Chapman, G., Jaekel, R., Schuster-Gossler, K., Cordes, R., Sparrow, D. B., Kremmer, E., Dunwoodie, S. L., Klein, T., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200702009 · Cited by 164 · see citing works
Antibody-targeted chemotherapy with immunoconjugates of calicheamicin
Damle, N. K. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00083-3 · Cited by 154 · see citing works
Maytansine
Issell, B. F., & Crooke, S. T. (1978) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(78)80014-0 · Cited by 151 · see citing works
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 145 · see citing works
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 140 · see citing works
Self-citation
Fundamental Relationships between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065
MacMillan, K. S., & Boger, D. L. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9006214 · Cited by 140 · see citing works
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Vaishampayan, U. N., Glodé, M., Du, W., Kraft, A. S., Hudes, G. R., Wright, J. D., & Hussain, M. (2000) · PubMed · Cited by 135 · see citing works
The next generation of antibody-drug conjugates comes of age.
Beck, A., Haeuw, J., Wurch, T., et al. (2010) · PubMed · Cited by 120 · see citing works
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Bendell, J. C., Saleh, M. N., Rose, A. A. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5683 · Cited by 108 · see citing works
Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
Faltas, B. M., Goldenberg, D. M., Ocean, A. J., Govindan, S. V., Wilhelm, F. E., Sharkey, R. M., Hajdenberg, J. J., Hodes, G., Nanus, D. M., & Tagawa, S. T. (2015) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2015.10.002 · Cited by 106 · see citing works
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H. M., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E. M., Green, J. A., Hawthorne, T. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97 · see citing works
Brentuximab vedotin
Ansell, S. M. (2014) · Blood · doi:10.1182/blood-2014-06-537514 · Cited by 87 · see citing works
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
Daver, N. G., Kantarjian, H. M., Ravandi, F., Estey, E. H., Wang, X., Garcia‐Manero, G., Jabbour, E. J., Konopleva, M. Y., O'Brien, S., Verstovšek, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.244 · Cited by 73 · see citing works
Antibody–Drug Conjugate Payloads
Anderl, J., Faulstich, H., Hechler, T., & Kulke, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_4 · Cited by 72 · see citing works
Investigational antibody-drug conjugates for hematological malignancies
Polson, A. G., Ho, W., & Ramakrishnan, V. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539557 · Cited by 71 · see citing works
Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., Kim, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0481 · Cited by 67 · see citing works
New Life for Immunotoxin Cancer Therapy
Hassan, R., Alewine, C., & Pastan, I. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1623 · Cited by 52 · see citing works
Self-citation
Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death
Gardai, S. J., Epp, A., & Law, C. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2469 · Cited by 47 · see citing works
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
Wagner‐Johnston, N. D., Goy, A. H., Rodriguez, M. A., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1017821 · Cited by 39 · see citing works
Immune markers in hematologic malignancies
Vaickus, L. J., Ball, E. D., & Foon, K. A. (1991) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(91)90029-c · Cited by 38 · see citing works
Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR).
Blumenschein, G. R., Hassan, R., Moore, K. N., Santin, A. D., Kindler, H. L., Nemunaitis, J. J., Seward, S. M., Rajagopalan, P., Walter, A. O., Sarapa, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2509 · Cited by 37 · see citing works
Self-citation
Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update
Martino, B., le Coutre, P., Grießhammer, M., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3197.3197 · Cited by 32 · see citing works
Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).
Thompson, J. A., Motzer, R. J., Molina, A. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2503 · Cited by 25 · see citing works
A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).
Gan, H. K., Fichtel, L., Lassman, A. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2021 · Cited by 22 · see citing works
A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma
Small, E. J., Figlin, R. A., Petrylak, D. P., et al. (2000) · Investigational New Drugs · doi:10.1023/a:1006386115312 · Cited by 20 · see citing works
Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study
Yasenchak, C. A., Farber, C. M., Budde, L. E., et al. (2014) · Blood · doi:10.1182/blood.v124.21.1745.1745 · Cited by 17 · see citing works
Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.
Borghaei, H., O’Malley, D. M., Seward, S. M., Bauer, T. M., Perez, R. P., Oza, A. M., Jeong, W., Michenzie, M. F., Kirby, M. W., Chandorkar, G., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5558 · Cited by 16 · see citing works
Abstract A135: T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner.
Mahapatra, K., Darbonne, W. C., Bumbaca, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-a135 · Cited by 15 · see citing works
Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.
Bardia, A., Vahdat, L. T., Diamond, J. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1016 · Cited by 12 · see citing works
Activity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: Phase I study.
Dotan, E., Berlin, J. D., Starodub, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3106 · Cited by 8 · see citing works
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.
Almhanna, K., Messersmith, W. A., Ahnert, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.tps3646 · Cited by 3 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[37]Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812– 21. 21047225

Sorted by citations

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229 · see citing works
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192 · see citing works
Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137 · see citing works
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31 · see citing works
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6 · see citing works

Brentuximab vedotin. an antibody-drug conjugate targeting CD30
Yanai, T. (2017) · Drug Delivery System · doi:10.2745/dds.32.126
Brentuximab vedotin
Younes, A., Yasothan, U., & Kirkpatrick, P. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3629 · Cited by 170 · see citing works
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 767 · see citing works
696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo
Grogan, B. M., James, R. D., Ulrich, M. L., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0696 · Cited by 1 · see citing works
Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review
Sassoon, I., & Blanc, V. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_1 · Cited by 157 · see citing works

Authors: Thomas, A., Teicher, B. A., & Hassan, R.
Affiliations: National Institutes of Health (US)
Corresponding author: Hassan, Raffit
ORCID: Thomas, Anish
Teicher, Beverly A
Hassan, Raffit
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-06
Volume: 17
Issue: 6
Pages: e254-e262
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30030-4
PMC: PMC6601617
OpenAlex: W2417431203
Cited by: 606
References: 76
Citations by year: 2026: 43 · 2025: 57 · 2024: 66 · 2023: 84 · 2022: 82 · 2021: 74 · 2020: 50 · 2019: 43 · 2018: 47 · 2017: 49 · 2016: 10
FWCI: 7.64
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01BC010816)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords: antibody-drug conjugates, monoclonal antibodies, cytotoxic payloads, tumor targeting, trastuzumab emtansine, brentuximab vedotin, combination therapy, immunotherapy, cancer therapy
MeSH terms: Antibodies, Monoclonal, Humans, Neoplasms, Immunoconjugates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antibody–drug conjugates for cancer therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks